Top Markets
#1 Black Phoenix Black Phoenix +342.81%
#2 Glidr Glidr +84.34%
#3 Akedo Akedo +61.75%
#4 Gold Park Gold Park +55.03%
#5 Acurast Acurast +36.76%
#6 BasedHype BasedHype +29.90%
#7 Cryptopia Cryptopia +22.04%
#8 Avantis Avantis +20.86%
#9 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +19.03%
#10 Quantum Resistant Ledger Quantum Resistant Ledger +14.74%
Coin of the day
Black Phoenix Black Phoenix
Innstillinger
Språk
NORSK
Valuta
USD
Tema
PaxMedica, Inc. Common Stock PaxMedica, Inc. Common Stock

PaxMedica, Inc. Common Stock

PXMD
Rangering i aksjer #40911
PaxMedica, Inc. is a biopharmaceutical company currently in the clinical... PaxMedica, Inc. is a biopharmaceutical company currently in the clinical development phase, dedicated to advancing anti-purinergic drug therapies (APTs). These innovative treatments are specifically designed to address complex neurological disorders presenting with stubborn and persistent symptoms. The company's primary investigative drug is PAX-101, an intravenous (IV) form of suramin, which is being explored for a variety of conditions. These include autism spectrum disorder, myalgic encephalomyelitis/chronic fatigue syndrome, post-COVID-19 syndrome (commonly known as "long COVID"), and human African trypanosomiasis. Furthermore, PaxMedica is also developing PAX-102, an intranasal version of suramin, intended for various neurological applications. The company, which was incorporated in 2018 and has its headquarters in Tarrytown, New York, previously operated as Purinix Pharmaceuticals LLC before rebranding to PaxMedica, Inc. in April 2020. It functions as a subsidiary of Tardimed Sciences LLC.
Aksjekurs
$0.0005
Sist synkronisert: 2026-08-12
Markedsverdi
$63.13K
Endring (1 dag)
0.00%
Endring (1 år)
150.00%
Land
US
Handel PaxMedica, Inc. Common Stock (PXMD)

Kategori

Healthcare
P/E-forhold for PaxMedica, Inc. Common Stock (PXMD)
P/E-forhold per 2026 TTM: 0
Ifølge PaxMedica, Inc. Common Stock sine siste finansielle rapporter og aksjekurs er selskapets nåværende P/E-forhold (TTM) 0. Ved slutten av 2026 hadde selskapet en P/E på 0.
P/E-forholdshistorikk for PaxMedica, Inc. Common Stock fra 2026 til 2026
P/E-forhold ved slutten av hvert år
År P/E-forhold Endre
Ikke nok data for de angitte datoene.
P/E-forhold for lignende selskaper eller konkurrenter
Selskap P/E-forhold Forskjell i P/E-forhold Land
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 28.05 -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 31.14 -
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
 - -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
 19.30 -
BE
Hvordan lese en P/E-ratio?

Pris/inntjening-forholdet (P/E) måler forholdet mellom aksjekursen og inntjening per aksje.
En lav men positiv P/E indikerer høy inntjening sammenlignet med nåværende verdsettelse, og kan tyde på at selskapet er undervurdert. En høy negativ (nær 0) P/E indikerer store tap.

Selskaper med P/E over 30 eller negativ betraktes vanligvis som "vekstaksjer", hvor investorer forventer vekst eller fremtidig lønnsomhet.

Selskaper med en positiv P/E under 10 anses vanligvis som "verdiaksjer", det vil si at selskapet allerede er lønnsomt, men har begrenset vekstpotensial.